The randomized, open-label, multicenterTRAIN-2trial (NCT01996267) evaluated the optimal chemotherapy backbone to use with neoadjuvant pertuzumab and trastuzumab in patients with stage II to stage III HER2-positive breast cancer (i.e., an anthracycline-containing or nonâ€“anthracycline-containing regimen).[126,127][Level of evidence B3] A total of 438 patients were randomly assigned to receive one of the following regimens: FEC every 3 weeks for three cycles followed by paclitaxel and carboplatin every 3 weeks for six cycles.
Paclitaxel was administered on days 1 and 8 and carboplatin was administered either on day 1 alone or on days 1 and 8.